About Aisa Pharma

Our Company

Aisa Pharma is a privately held, clinical-stage biopharmaceutical development company dedicated to bringing new disease-modifying treatments to patients with rare serious diseases that have few effective treatment options.

We focus on repurposing and optimizing select calcium channel blockers to create differentiated therapies with the potential to improve both efficacy and tolerability for underserved patient populations.

Our lead program is developing an oral therapy targeting N-type calcium channels for patients with Raynaud’s phenomenon associated with systemic sclerosis (scleroderma), a severe autoimmune disease with significant unmet medical need. We advance our development strategy with a disciplined, data-driven approach and an experienced team of industry leaders, consultants, and scientific advisors who have successfully guided multiple therapies from concept through late-stage clinical development and approval.

Aisa Pharma, Inc. is headquartered in the Beacon Hill section of Boston, Massachusetts, with additional presence in Sydney, Australia. We collaborate globally with clinicians, investigators, and partners who share our commitment to improving outcomes for patients living with rare vascular and autoimmune diseases.